Cargando…
The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice
BACKGROUND: E2HSA is a genetic fusion protein that consists of two tandem exendin-4 molecules that are covalently bonded to recombinant human serum albumin via a peptide linker. Previous studies have demonstrated that E2HSA significantly decreased blood glucose levels, improved β-cell function and p...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477380/ https://www.ncbi.nlm.nih.gov/pubmed/28629388 http://dx.doi.org/10.1186/s40360-017-0143-8 |
_version_ | 1783244780131581952 |
---|---|
author | Li, Caina Hou, Shaocong Liu, Shuainan Huan, Yi Sun, Sujuan Liu, Quan Shen, Zhufang |
author_facet | Li, Caina Hou, Shaocong Liu, Shuainan Huan, Yi Sun, Sujuan Liu, Quan Shen, Zhufang |
author_sort | Li, Caina |
collection | PubMed |
description | BACKGROUND: E2HSA is a genetic fusion protein that consists of two tandem exendin-4 molecules that are covalently bonded to recombinant human serum albumin via a peptide linker. Previous studies have demonstrated that E2HSA significantly decreased blood glucose levels, improved β-cell function and promoted β-cell proliferation in diabetic db/dB mice. This study aimed to evaluate the benefits of E2HSA on glucose and lipid metabolism in a spontaneous diabetes animal model, KKAy mice. METHODS: E2HSA was acutely administered at doses of 1, 3 and 9 mg/kg by subcutaneous injection in diabetic KKAy mice with exendin-4 (2 μg/kg) as a positive reference, and then the non-fasting blood glucose and food intake levels were dynamically monitored. In addition, different doses of E2HSA were injected once daily, as well as with exendin-4 twice daily, for 7 weeks to evaluate the effect on glucose and lipid metabolism, as well as the body weight, food and water intake. RESULTS: Single injection of E2HSA decreased non-fasting blood glucose and food intake levels in a dose-dependent manner for 4 days and 2 days, respectively. Repeated injections with E2HSA significantly decreased variations in blood glucose levels with a reduction of HbA1c levels by 1.6% at a 9 mg/kg dose, simultaneously increased fasting blood insulin levels, inhibited fasting blood glucagon levels, improved the impaired oral glucose tolerance and enhanced glucose infusion rate, which is the gold standard for evaluating β-cell function. Moreover, repeated injections with E2HSA also ameliorated the dyslipidemia and reduced body weight, food and water intake in diabetic KKAy mice. CONCLUSIONS: E2HSA significantly reduced blood glucose levels over a prolonged duration, enhanced β-cell function, and ameliorated dyslipidemia and obesity in diabetic KKAy mice. Thus, E2HSA may be a new candidate for the treatment of type 2 diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-017-0143-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5477380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54773802017-06-23 The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice Li, Caina Hou, Shaocong Liu, Shuainan Huan, Yi Sun, Sujuan Liu, Quan Shen, Zhufang BMC Pharmacol Toxicol Research Article BACKGROUND: E2HSA is a genetic fusion protein that consists of two tandem exendin-4 molecules that are covalently bonded to recombinant human serum albumin via a peptide linker. Previous studies have demonstrated that E2HSA significantly decreased blood glucose levels, improved β-cell function and promoted β-cell proliferation in diabetic db/dB mice. This study aimed to evaluate the benefits of E2HSA on glucose and lipid metabolism in a spontaneous diabetes animal model, KKAy mice. METHODS: E2HSA was acutely administered at doses of 1, 3 and 9 mg/kg by subcutaneous injection in diabetic KKAy mice with exendin-4 (2 μg/kg) as a positive reference, and then the non-fasting blood glucose and food intake levels were dynamically monitored. In addition, different doses of E2HSA were injected once daily, as well as with exendin-4 twice daily, for 7 weeks to evaluate the effect on glucose and lipid metabolism, as well as the body weight, food and water intake. RESULTS: Single injection of E2HSA decreased non-fasting blood glucose and food intake levels in a dose-dependent manner for 4 days and 2 days, respectively. Repeated injections with E2HSA significantly decreased variations in blood glucose levels with a reduction of HbA1c levels by 1.6% at a 9 mg/kg dose, simultaneously increased fasting blood insulin levels, inhibited fasting blood glucagon levels, improved the impaired oral glucose tolerance and enhanced glucose infusion rate, which is the gold standard for evaluating β-cell function. Moreover, repeated injections with E2HSA also ameliorated the dyslipidemia and reduced body weight, food and water intake in diabetic KKAy mice. CONCLUSIONS: E2HSA significantly reduced blood glucose levels over a prolonged duration, enhanced β-cell function, and ameliorated dyslipidemia and obesity in diabetic KKAy mice. Thus, E2HSA may be a new candidate for the treatment of type 2 diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-017-0143-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-19 /pmc/articles/PMC5477380/ /pubmed/28629388 http://dx.doi.org/10.1186/s40360-017-0143-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Li, Caina Hou, Shaocong Liu, Shuainan Huan, Yi Sun, Sujuan Liu, Quan Shen, Zhufang The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice |
title | The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice |
title_full | The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice |
title_fullStr | The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice |
title_full_unstemmed | The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice |
title_short | The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice |
title_sort | albumin-exendin-4 recombinant protein e2hsa improves glycemic control and β-cell function in spontaneous diabetic kkay mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477380/ https://www.ncbi.nlm.nih.gov/pubmed/28629388 http://dx.doi.org/10.1186/s40360-017-0143-8 |
work_keys_str_mv | AT licaina thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice AT houshaocong thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice AT liushuainan thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice AT huanyi thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice AT sunsujuan thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice AT liuquan thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice AT shenzhufang thealbuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice AT licaina albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice AT houshaocong albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice AT liushuainan albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice AT huanyi albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice AT sunsujuan albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice AT liuquan albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice AT shenzhufang albuminexendin4recombinantproteine2hsaimprovesglycemiccontrolandbcellfunctioninspontaneousdiabetickkaymice |